Journal
JOURNAL OF CONTROLLED RELEASE
Volume 362, Issue -, Pages 184-196Publisher
ELSEVIER
DOI: 10.1016/j.jconrel.2023.08.052
Keywords
Angiogenesis; Biomaterials; Growth factor; Perlecan; Vascularisation; Wound healing
Ask authors/readers for more resources
Growth factors play a crucial role in angiogenesis for tissue repair and regeneration. However, the clinical success of growth factor delivery has been limited. This study demonstrates that engineered short forms of perlecan can bind and activate angiogenic growth factors. Delivery of these engineered perlecan forms in chitosan scaffolds promotes angiogenesis, making them potential next generation angiogenic therapies.
Growth factors are key molecules involved in angiogenesis, a process critical for tissue repair and regeneration. Despite the potential of growth factor delivery to stimulate angiogenesis, limited clinical success has been achieved with this approach. Growth factors interact with the extracellular matrix (ECM), and particularly heparan sulphate (HS), to bind and potentiate their signalling. Here we show that engineered short forms of perlecan, the major HS proteoglycan of the vascular ECM, bind and signal angiogenic growth factors, including fibroblast growth factor 2 and vascular endothelial growth factor-A. We also show that engineered short forms of perlecan delivered in porous chitosan biomaterial scaffolds promote angiogenesis in a rat full thickness dermal wound model, with the fusion of perlecan domains I and V leading to superior vascularisation compared to native endothelial perlecan or chitosan scaffolds alone. Together, this study demonstrates the potential of engineered short forms of perlecan delivered in chitosan scaffolds as next generation angiogenic therapies which exert biological activity via the potentiation of growth factors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available